SAB Biotherapeutics, Inc. (SABS) NASDAQ

1.75

+0.25(+16.67%)

Updated at April 25 04:00PM

Currency In USD

SAB Biotherapeutics, Inc.

Address

2100 East 54th Street North

Sioux Falls, SD 57104

United States of America

Phone

605 679 6980

Sector

Healthcare

Industry

Biotechnology

Employees

63

First IPO Date

February 09, 2021

Key Executives

NameTitlePayYear Born
Mr. Samuel J. ReichChief Executive Officer & Executive Chairman782,1001975
Ms. Christine E. Hamilton M.B.A.Co-Founder & Independent Director32,0001956
Ms. Lucy ToExecutive Vice President & Chief Financial Officer165,1311986
Dr. Christoph Bausch M.B.A., Ph.D.Executive Vice President & Chief Operating Officer574,5851971
Dr. Eddie Joe Sullivan Ph.D.Co-Founder, President & Director744,3821967
Dr. Alexandra Kropotova M.B.A., M.D.Executive Vice President & Chief Medical Officer790,1501973
Dr. Carlos N. Carillo Ph.D.Senior Vice President of Regulatory Affairs0N/A
Dr. Edward D. Hamilton D.V.M.Co-Founder & Board Observer0N/A

Description

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.